A 58-year-old Indian man presents to the ophthalmology clinic for routine eye checkup. He is asymptomatic and has no ocular complaints. On examination, visual acuity is 6/6 in both eyes. Intraocular pressure (IOP) measured by applanation tonometry is 24 mmHg in the right eye and 22 mmHg in the left eye. Gonioscopy reveals open angles in all four quadrants bilaterally. Optic disc examination shows a cup-to-disc ratio of 0.7 with inferior notching and nasal shifting of vessels. Optical coherence tomography (OCT) of the optic nerve head confirms thinning of the neuroretinal rim superiorly and inferiorly. Visual field testing by automated perimetry shows a superior arcuate defect in the right eye. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Primary Open-Angle Glaucoma (POAG) ### Key Diagnostic Features Present | Feature | Finding | Significance | |---------|---------|---------------| | IOP | 24 mmHg (elevated) | Above statistical normal range (>21 mmHg) | | Gonioscopy | Open angles all quadrants | Rules out angle-closure mechanism | | Optic disc | Cup-to-disc 0.7, inferior notching, nasal vessel shift | Characteristic glaucomatous optic neuropathy | | OCT | Neuroretinal rim thinning | Structural evidence of axonal loss | | Visual field | Superior arcuate defect | Functional evidence of glaucomatous damage | | Symptoms | Asymptomatic | Typical for POAG (silent disease) | ### Management Algorithm for NEWLY DIAGNOSED POAG ```mermaid flowchart TD A[POAG confirmed: elevated IOP + optic neuropathy + VF defect]:::outcome A --> B{Severity of glaucomatous damage?}:::decision B -->|Mild-moderate, no prior treatment| C[Start topical monotherapy]:::action B -->|Severe or advanced| D[Consider combination therapy or laser/surgery]:::action C --> E[Prostaglandin analogue first-line]:::action E --> F[Latanoprost, travoprost, or bimatoprost]:::action F --> G[Recheck IOP in 4 weeks]:::action G --> H{Target IOP achieved?}:::decision H -->|Yes| I[Continue, monitor 3-6 monthly]:::outcome H -->|No| J[Add second agent or escalate]:::action ``` **Key Point:** In newly diagnosed POAG with mild-to-moderate damage and no prior treatment, **topical medical therapy is first-line**. Prostaglandin analogues (latanoprost, travoprost, bimatoprost) are preferred initial agents due to superior efficacy (25–35% IOP reduction) and once-daily dosing, improving compliance [cite:Spaeth Glaucoma Ch 8]. **High-Yield:** The patient has documented glaucomatous optic neuropathy (cup-to-disc 0.7, notching, rim thinning on OCT) AND functional loss (arcuate VF defect) — this confirms POAG diagnosis and mandates treatment initiation. **Clinical Pearl:** Asymptomatic presentation is the hallmark of POAG. Most patients are detected incidentally during routine screening or when referred for elevated IOP. This patient's superior arcuate defect corresponds to inferior optic disc damage (arcuate nerve fiber bundle loss). **Mnemonic: POAG First-Line Agents — "PLUMB"** - **P**rostaglandin analogues (latanoprost, travoprost, bimatoprost) - **L**atanoprost (most commonly used) - **U**niversal first-line choice - **M**onotherapy initiation standard - **B**imatoprost (alternative PGA) ### Why NOT the Other Options? **Laser peripheral iridotomy (option B):** Indicated only in angle-closure glaucoma or narrow angles. Gonioscopy here shows open angles in all quadrants — iridotomy is contraindicated and ineffective in POAG. **Oral acetazolamide (option C):** Reserved for acute angle-closure crisis or as adjunctive therapy in refractory POAG. Not appropriate as monotherapy for newly diagnosed POAG; topical agents are preferred to minimize systemic side effects. **Trabeculectomy (option D):** Surgical intervention reserved for advanced glaucoma with poor medical control, rapid progression, or severe damage. This patient has mild-to-moderate disease with no prior medical therapy — surgery is premature.